Berberine 1,500mg Cuts BMI by 2.8 and Weight by 7.4kg — 12-Week RCT, GLP-1 Era Natural Option
WELLNESS

Berberine 1,500mg Cuts BMI by 2.8 and Weight by 7.4kg — 12-Week RCT, GLP-1 Era Natural Option

By Léa · · https://onlinelibrary.wiley.com/journal/1930739x
KO | EN

A 12-week RCT in 248 obese (BMI 30+) adults taking berberine 1,500mg showed mean weight -7.4kg and BMI -2.8 kg/m². Published in the February 2026 issue of Obesity, the joint Sydney Medical School-Beijing Medical College trial showed 75% of GLP-1 agonist (liraglutide) efficacy with less than half the side effects.

Researchers randomized 248 patients (mean 47, 64% female) with BMI 30~38 plus diabetes or prediabetes into four arms. (1) Berberine 1,500mg (500mg before each meal), (2) Liraglutide 3.0mg/day subcutaneous (GLP-1), (3) Berberine + liraglutide, (4) Placebo. All arms received standard lifestyle intervention (-500 kcal/day diet + 150 min/week exercise). Primary endpoint was 12-week weight change. Secondary endpoints included BMI, waist circumference, visceral fat (DEXA), HbA1c, lipids, and adverse events.

Twelve-week weight changes: berberine -7.4kg (-7.8%), liraglutide -8.6kg (-9.0%, statistically significant difference), combined -10.2kg (-10.7%), placebo -2.4kg (-2.6%). Berberine achieved 75% of liraglutide’s efficacy as a natural food ingredient. Combined therapy yielded the largest effect.

BMI: berberine -2.8 kg/m² (liraglutide -3.2, placebo -0.9), waist circumference -8.2cm (liraglutide -9.4, placebo -2.4), visceral fat -22% (liraglutide -24%, placebo -6%). Berberine showed not just simple weight loss but a clinically meaningful pattern of visceral fat reduction + waist circumference reduction. Greater visceral than subcutaneous fat reduction connects directly to insulin resistance + metabolic syndrome improvement.

Metabolic markers consistently favored berberine. HbA1c -0.5 percentage points (liraglutide -0.6, placebo -0.1), fasting glucose -16 mg/dL, triglycerides -38 mg/dL, LDL -22 mg/dL, HDL +6 mg/dL, hs-CRP -28%. Triglyceride reduction of -38 mg/dL was superior to liraglutide’s -28 mg/dL — berberine’s PCSK9 expression -32% inhibition + LDL receptor +28% expression directly modulates lipid metabolism.

The most clinically meaningful difference was adverse events. Berberine 12.4% (mild GI discomfort, constipation, weeks 1~2 only), liraglutide 28.6% (nausea 24%, vomiting 12%, diarrhea 16%), combined 22.4%, placebo 8.2%. Liraglutide’s GLP-1 agonist-typical GI side effects cause 35~50% discontinuation within 12 weeks in real-world clinical data. Berberine’s discontinuation rate was 4.4%, very low.

In 24-week follow-up, weight maintenance was 82% in berberine, 64% in liraglutide, 38% in placebo. Berberine showed less weight regain after discontinuation. GLP-1 agents are known to cause 75~85% weight regain within 6~12 months of discontinuation. Berberine demonstrated the clinical value of a less drug-dependent natural option.

Berberine’s mechanism spans five axes. First, AMPK direct activation (same target as metformin). Second, insulin receptor IRS-1 phosphorylation recovery. Third, GLUT4 membrane translocation increasing muscle glucose uptake. Fourth, PCSK9 inhibition + LDL receptor increase for lipid metabolism. Fifth, gut microbiota modulation (Akkermansia +28%, Bacteroides diversity). Mechanism directly addresses obesity’s core pathology (insulin resistance + chronic inflammation + lipid abnormality + gut imbalance).

Adverse events at 12.4% in berberine were less than half of GLP-1 agonists. However, pregnancy, lactation, anticoagulant (warfarin), cyclosporine, and digoxin users require clinician consultation. CYP3A4 and P-glycoprotein inhibition causes drug interactions. Newborn jaundice risk contraindicates use during newborn breastfeeding.

Korean obesity prevalence is BMI 25+ 38.4% and BMI 30+ 7.2% per 2026 KNHANES. GLP-1 agonists (semaglutide, liraglutide) are first-line drugs but limited by 500K~1M KRW monthly cost + 35~50% discontinuation rates. This trial positions berberine 1,500mg in four clinical roles: (1) GLP-1 side-effect discontinuation patients, (2) GLP-1 cost-burden patients, (3) GLP-1 + berberine combined for enhanced efficacy, (4) post-GLP-1 weight maintenance. Pregnancy potential, newborn breastfeeding, and polypharmacy patients warrant clinician consultation first.